U.S. markets closed
  • S&P Futures

    4,306.75
    -1.00 (-0.02%)
     
  • Dow Futures

    34,120.00
    +2.00 (+0.01%)
     
  • Nasdaq Futures

    13,645.75
    -12.50 (-0.09%)
     
  • Russell 2000 Futures

    2,024.20
    +0.90 (+0.04%)
     
  • Crude Oil

    87.12
    +0.59 (+0.68%)
     
  • Gold

    1,789.90
    +0.20 (+0.01%)
     
  • Silver

    20.04
    -0.04 (-0.22%)
     
  • EUR/USD

    1.0177
    +0.0006 (+0.06%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Vix

    19.69
    -0.26 (-1.30%)
     
  • GBP/USD

    1.2107
    +0.0013 (+0.11%)
     
  • USD/JPY

    134.1220
    -0.0930 (-0.07%)
     
  • BTC-USD

    24,042.79
    -72.74 (-0.30%)
     
  • CMC Crypto 200

    573.09
    +1.17 (+0.20%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    29,120.30
    +251.39 (+0.87%)
     

Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd.

HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022, at 8:30 a.m. Eastern Time to report its second quarter 2022 financial results and corporate activities.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (international) using conference ID number 1606846.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com